Brandi, ML, Gagel, RF, Angeli, A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001), 5658–5671.
Chandrasekharappa, SC, Guru, SC, Manickam, P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 (1997), 404–407.
Thakker, RV, Newey, PJ, Walls, GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97 (2012), 2990–3011.
Brandi, ML, Pieterman, CRC, English, KA, et al. Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice. Lancet Diabetes Endocrinol, 2025 published online June 13. https://doi.org/10.1016/S2213-8587(25)00119-6.
English, KA, Pieterman, CRC, Marini, F, et al. Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis. Lancet Diabetes Endocrinol, 2025 published online June 13. https://doi.org/10.1016/S2213-8587(25)00118-4.
Gray, WK, Navaratnam, AV, Day, J, Wass, JAH, Briggs, TWR, Lansdown, M, Volume-outcome associations for parathyroid surgery in England: analysis of an administrative data set for the Getting It Right First Time Program. JAMA Surg 157 (2022), 581–588.
Vergès, B, Boureille, F, Goudet, P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France–Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87 (2002), 457–465.
de Laat, JM, Dekkers, OM, Pieterman, CRC, et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab 100 (2015), 3288–3296.
Vroonen, L, Jaffrain-Rea, M-L, Petrossians, P, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167 (2012), 651–662.
Newey, PJ, Newell-Price, J, MEN1 surveillance guidelines: time to (re)think?. J Endocr Soc 6 (2022), 1–5.
